Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
SGMT Sagimet Biosciences Inc
- Stocks
- Healthcare
- NASDAQ: SGMT
Price (delayed)
$3.22
Market cap
$103.67M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.76
Enterprise value
$38.99M
We are a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic pathways in diseases resulting from the overproduction of the fatty acid,
Highlights
The EPS has soared by 95% YoY but it has decreased by 21% from the previous quarter
The debt has plunged by 50% from the previous quarter but it has soared by 50% YoY
The net income has dropped by 105% year-on-year and by 25% since the previous quarter
Sagimet Biosciences's gross profit has shrunk by 100% YoY
Key stats
What are the main financial stats of SGMT
Market
Valuations
Earnings
Shares outstanding
32.2M
Market cap
$103.67M
Enterprise value
$38.99M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.75
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$65.55M
Net income
-$57.11M
EBIT
-$57.11M
EBITDA
-$56.97M
Free cash flow
-$50.76M
Per share
Balance sheet
Liquidity
EPS
-$1.76
EPS diluted
-$1.76
Free cash flow per share
-$1.58
Book value per share
$4.32
Revenue per share
$0
TBVPS
$4.54
Total assets
$146.17M
Total liabilities
$7.18M
Debt
$39,000
Equity
$138.99M
Working capital
$138.89M
Debt to equity
0
Current ratio
20.34
Quick ratio
20.13
Net debt/EBITDA
1.14
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-34.1%
Return on equity
-35.2%
Return on invested capital
-68.1%
Return on capital employed
-41.1%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
SGMT stock price
How has the Sagimet Biosciences stock price performed over time
Intraday
-2.72%
1 week
-1.23%
1 month
59.41%
1 year
-32.21%
YTD
-28.44%
QTD
-1.23%
Financial performance
How have Sagimet Biosciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$65.55M
Net income
-$57.11M
Gross margin
N/A
Net margin
N/A
The net income has dropped by 105% year-on-year and by 25% since the previous quarter
Sagimet Biosciences's gross profit has shrunk by 100% YoY
The company's revenue has shrunk by 100% YoY
SGMT's operating income has shrunk by 100% YoY and by 20% QoQ
Price vs fundamentals
How does SGMT's price correlate with its fundamentals
Growth
What is Sagimet Biosciences's growth rate over time
Valuation
What is Sagimet Biosciences stock price valuation
P/E
N/A
P/B
0.75
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has soared by 95% YoY but it has decreased by 21% from the previous quarter
The equity has declined by 27% year-on-year and by 11% since the previous quarter
SGMT's price to book (P/B) is 7% higher than its last 4 quarters average of 0.7
The company's revenue has shrunk by 100% YoY
Efficiency
How efficient is Sagimet Biosciences business performance
The return on invested capital has surged by 86% year-on-year but it has declined by 2.6% since the previous quarter
The company's return on equity rose by 43% YoY but it fell by 35% QoQ
Sagimet Biosciences's return on assets has decreased by 34% QoQ and by 27% YoY
Dividends
What is SGMT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for SGMT.
Financial health
How did Sagimet Biosciences financials performed over time
Sagimet Biosciences's total liabilities has surged by 61% QoQ and by 59% YoY
Sagimet Biosciences's current ratio has shrunk by 53% YoY and by 41% QoQ
The debt is 100% less than the equity
The debt has plunged by 50% from the previous quarter but it has soared by 50% YoY
The equity has declined by 27% year-on-year and by 11% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.